
Opinion|Videos|March 13, 2026
Remaining Evidence Gaps in EGFR-Mutated NSCLC Care
Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, discuss remaining evidence gaps in EGFR-mutated NSCLC care.
Advertisement
Episodes in this series

Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, identify persistent evidence gaps in the management of EGFR-mutated non–small cell lung cancer. Vokes highlights unanswered questions regarding optimal combination strategies, duration of therapy, and sequencing after novel frontline regimens. Devarakonda underscores the need for biomarker-driven research and real-world data to refine treatment algorithms.
Advertisement
Related to this article

The FDA granted fast track designation to elticertinib for pretreated EGFR exon 20 insertion–mutated NSCLC.

Phase 2 NB2012 data showed a 3-year event-free survival rate of 73.7% with daretabart plus induction chemotherapy.

Deepa Rangachari, MD, discusses community oncology training, goal-concordant mentorship, genomic fluency, and multidisciplinary care.

Mayo Clinic researchers identified BRCA2 variants linked to moderate breast cancer risk, potentially informing personalized screening and prevention.

Experts weigh in on standout breast cancer, lung cancer, melanoma, and kidney cancer data presented at the 2026 ESMO Congress.

Maintenance galinpepimut-S extended overall survival in transplant-ineligible AML in second or later remission.

Longer follow-up of KANDLELIT-001 supports frontline calderasib plus pembrolizumab in KRAS G12C–mutated metastatic non–small cell lung cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Removes Limitations of Use for Liso-Cel in Primary Central Nervous System Lymphoma
2
Sintilimab Receives Positive CHMP Opinion for First-Line Nonsquamous NSCLC
3
Galinpepimut-S Improves OS in AML in Second or Later Remission
4
ESMO 2026 Data Highlight ADC Activity in Brain Metastases and TNBC
5

